Compare Adaptive Biotechnologies Corp (ADPT) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs DENTSPLY SIRONA Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while DENTSPLY SIRONA Inc trades at $11.76 (market cap $2.44B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | XRAY | |
|---|---|---|
Market Cap | $3.33B | $2.44B |
Sector | Health | Health |
52-Week High | $22.37 | $16.85 |
52-Week Low | $10.24 | $9.64 |
Enterprise Value | $3.19B | $4.58B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
XRAY trades at $12.19, up 4.64% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q1 2026 EPS of $0.27, missing estimates of $0.28, continuing a trend of earnings misses. Revenue declined to $3.68B in 2025 with a net loss of $598M, though gross margin remains healthy at 48.93%. Recent news highlights distribution expansions and AI-enabled product launches, supporting growth initiatives amid ongoing profitability challenges.
The outlook remains mixed: analyst consensus is a 'Hold' with a $12.50 price target, near current levels. Upside potential exists from digital dentistry adoption and cost controls, but risks include persistent net losses, high debt-to-asset ratio of 42.88%, and competitive pressures. Investors should weigh stabilization efforts against margin headwinds and macroeconomic softness in European markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
